Order Article Reprints

Versage E, van Twuijver E, Jansen W, Theeuwes A, Sawlwin D, Hohenboken M. Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults. Vaccines. 2021; 9(12):1468. https://doi.org/10.3390/vaccines9121468

Versage, Eve, Esther van Twuijver, Wim Jansen, Ad Theeuwes, Daphne Sawlwin, and Matthew Hohenboken. 2021. "Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults" Vaccines 9, no. 12: 1468. https://doi.org/10.3390/vaccines9121468

Versage, E., van Twuijver, E., Jansen, W., Theeuwes, A., Sawlwin, D., & Hohenboken, M. (2021). Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults. Vaccines, 9(12), 1468. https://doi.org/10.3390/vaccines9121468